Btk inhibitor 2

CAS No. 1558036-85-3

Btk inhibitor 2( BGB-3111 analog )

Catalog No. M23674 CAS No. 1558036-85-3

Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 75 In Stock
2MG 42 In Stock
5MG 68 In Stock
10MG 100 In Stock
25MG 227 In Stock
50MG 368 In Stock
100MG 448 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Btk inhibitor 2
  • Note
    Research use only, not for human use.
  • Brief Description
    Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
  • Description
    Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BGB-3111 analog
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1558036-85-3
  • Formula Weight
    431.49
  • Molecular Formula
    C24H25N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:75 mg/mL (173.82 mM; Need ultrasonic and warming)
  • SMILES
    C=CC(=O)N1CCC[C@H](C1)N2C(=C(C(=N2)C3=CC=C(C=C3)OC4=CC=CC=C4)C(=O)N)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Cecile M. Krejsa. Methods of Using BTK Inhibitors to Treat Dermatoses. US 20170224688 A1.
molnova catalog
related products
  • Tirabrutinib

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR.

  • BTK inhibitor 1

    BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.

  • BDTX-189

    BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.